Alexis L. Scott

A high density of macrophages in the ovarian cancer microenvironment is associated with disease progression and poor outcomes. Understanding cancer‐macrophage interaction mechanisms that establish this pro‐tumorigenic microenvironment is critical for developing macrophage‐targeted therapies. Here, 3D microfluidic assays and patient‐derived xenografts are utilized to define the role of cancer‐derived colony stimulating factor 1 (CSF1) on macrophage infiltration dynamics toward ovarian cancer cells. It is demonstrated that multiple ovarian cancer models promote the infiltration of macrophages into a 3D extracellular matrix in vitro in a cell density‐dependent manner. Macrophages exhibit directional migration and increased migration speed under both direct interactions with cancer cells embedded within the matrix and paracrine crosstalk with cancer cells seeded in an independent microchannel. It is also found that platinum‐based chemotherapy increases macrophage recruitment and the levels of cancer cell‐derived CSF1. Targeting CSF1 signaling under baseline or chemotherapy‐treatment conditions reduces the number of infiltrated macrophages. It is further shown that results obtained with the 3D microfluidic model reflect the recruitment profiles of macrophages in patient‐derived xenografts in vivo. These findings highlight the role of CSF1 signaling in establishing macrophage‐rich ovarian cancer microenvironments, as well as the utility of microfluidic models in recapitulating 3D tumor ecosystems and dissecting cancer‐macrophage signaling.

Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Legends for supplementary figures and tables.

Safetyscreen assay for C86 performed at eurofins.

Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

Table comparing various key pharmacokinetic parameters (Assay, left column) between C-91 and C-86.

Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma